

Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (http://www.dpic.org)

Home > Drug Product Listings > Golimumab > Printer-friendly PDF

Golimumab

Trade Name:

Simponi

Manufacturer/Distributor:

Schering-Plough

www.schering-plough.ca, 1-800-463-5442 (Medical Information)

Classification:

Tumor necrosis factor alpha inhibitor (DMARD)

ATC Class:

L04AB06 Golimumab

Status:

active

Notice of Compliance (yyyy/mm/dd):

2009/04/07

Date Marketed in Canada (yyyy/mm/dd):

2009/07

Presentation:

Injection: 50 mg/0.5 mL; DIN 02324784

Comments:

To be used in combination with methotrexate in adult patients with moderate to severe rheumatoid arthritis. It can also be used alone or in combination with methotrexate for psoriatic arthritis. As well, patients with ankylosing spondylitis, who have had inadequate responses from conventional therapies, may benefit from use of golimumab.

Source:

Letter from company

Access:

public

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?7mesh U?xwumixw (Squamish Nation), and s?l?ílw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this

site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-10-28 03:23): http://www.dpic.org/druglisting/golimumab